141 related articles for article (PubMed ID: 27842592)
1. Inconsistent approaches of the G-BA regarding acceptance of primary study endpoints as being relevant to patients - an analysis of three disease areas: oncological, metabolic, and infectious diseases.
Staab T; Isbary G; Amelung VE; Ruof J
BMC Health Serv Res; 2016 Nov; 16(1):651. PubMed ID: 27842592
[TBL] [Abstract][Full Text] [Related]
2. Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany.
Ruof J; Knoerzer D; Dünne AA; Dintsios CM; Staab T; Schwartz FW
Health Policy; 2014 Nov; 118(2):242-54. PubMed ID: 25194474
[TBL] [Abstract][Full Text] [Related]
3. Early benefit assessment (EBA) in Germany: analysing decisions 18 months after introducing the new AMNOG legislation.
Ruof J; Schwartz FW; Schulenburg JM; Dintsios CM
Eur J Health Econ; 2014 Jul; 15(6):577-89. PubMed ID: 23771769
[TBL] [Abstract][Full Text] [Related]
4. Early Benefit Assessments in Oncology in Germany: How Can a Clinically Relevant Endpoint Not Be Relevant to Patients?
Ruof J; Flückiger O; Andre N
Drugs R D; 2015 Sep; 15(3):221-6. PubMed ID: 26286202
[TBL] [Abstract][Full Text] [Related]
5. Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.
Dabisch I; Dethling J; Dintsios CM; Drechsler M; Kalanovic D; Kaskel P; Langer F; Ruof J; Ruppert T; Wirth D
Health Econ Rev; 2014 Jan; 4(1):2. PubMed ID: 24460706
[TBL] [Abstract][Full Text] [Related]
6. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
[TBL] [Abstract][Full Text] [Related]
7. Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany - are additional data requirements by the Federal Joint Committee justified?
Ruof J; Staab T; Dintsios CM; Schröter J; Schwartz FW
Health Econ Rev; 2016 Dec; 6(1):46. PubMed ID: 27687714
[TBL] [Abstract][Full Text] [Related]
8. "Market withdrawals" of medicines in Germany after AMNOG: a comparison of HTA ratings and clinical guideline recommendations.
Staab TR; Walter M; Mariotti Nesurini S; Dintsios CM; Graf von der Schulenburg JM; Amelung VE; Ruof J
Health Econ Rev; 2018 Sep; 8(1):23. PubMed ID: 30229501
[TBL] [Abstract][Full Text] [Related]
9. Four years of early benefit assessment of new drugs in Germany: a qualitative study on methodological requirements for quality of life data.
Blome C; Augustin M; Metin H; Lohrberg D
Eur J Health Econ; 2017 Mar; 18(2):181-193. PubMed ID: 26837412
[TBL] [Abstract][Full Text] [Related]
10. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
[TBL] [Abstract][Full Text] [Related]
11. [Patient-relevant outcomes and surrogates in the early benefit assessment of drugs: first experiences].
Kvitkina T; ten Haaf A; Reken S; McGauran N; Wieseler B
Z Evid Fortbild Qual Gesundhwes; 2014; 108(8-9):528-38. PubMed ID: 25523852
[TBL] [Abstract][Full Text] [Related]
12. Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective.
Kisser A; Knieriemen J; Fasan A; Eberle K; Hogger S; Werner S; Taube T; Rasch A
Eur J Health Econ; 2022 Jul; 23(5):863-878. PubMed ID: 34766242
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life (HRQoL) in German early benefit assessment: The importance of disease-specific instruments.
Kramer L; Moos M; Thaa B; Welte R; Esser M
Z Evid Fortbild Qual Gesundhwes; 2024 May; 186():1-9. PubMed ID: 38580503
[TBL] [Abstract][Full Text] [Related]
14. Failure due to formal reasons within German benefit assessment of medicinal products: the dilemma between marketing authorization and HTA.
Molitor M; Dintsios CM
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):145-157. PubMed ID: 32043904
[No Abstract] [Full Text] [Related]
15. [Involvement of scientific societies in early benefit assessment: Simulated participation or valuable additional input?].
Bleß HH; Seidlitz C; Ohlmeier C; de Millas C
Z Evid Fortbild Qual Gesundhwes; 2018 Feb; 130():49-57. PubMed ID: 29103831
[TBL] [Abstract][Full Text] [Related]
16. Leveraging EUnetHTA's conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer's point of view.
Giuliani G; Chassagnol F; Traub D; Gyldmark M; Hebborn A; Ducournau P; Ruof J
Health Econ Rev; 2018 Sep; 8(1):24. PubMed ID: 30242522
[TBL] [Abstract][Full Text] [Related]
17. [Cancer: Is it really so different? Particularities of oncologic drugs from the perspective of the pharmaceutical regulatory agency].
Enzmann H; Broich K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):120-8. PubMed ID: 23663906
[TBL] [Abstract][Full Text] [Related]
18. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
Fischer KE; Stargardt T
Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
[TBL] [Abstract][Full Text] [Related]
19. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
Schaefer R; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
[No Abstract] [Full Text] [Related]
20. Evaluation of a possible predictor for Federal Joint Committee decisions on early benefit assessments according to the German act on the reform of the market for medicinal products.
Schwander B; Banz K; Kaier K; Walzer S
Health Policy; 2014 Sep; 117(3):334-44. PubMed ID: 25059744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
